Recent data demonstrate that Donanemab, a experimental drug, has the potential to lessen the advance of preclinical dementia . This treatment targets clearing beta-amyloid in the mind, a https://socialmediainuk.com/story26687614/lecanemab-a-emerging-innovative-cognitive-treatment